The Best Topical For Psoriasis of 2022:
Best Over The Counter For Eczema of March 2022:
WE ARE ON THE MAP!
Out of 167, the Global Startup Heat Map highlights 5 Top Startups working on Microbe-derived Materials
The insights of this data-driven analysis are derived from the Big Data & Artificial Intelligence-powered StartUs Insights Discovery Platform, covering 2 093 000+ startups & scaleups globally. The platform gives you an exhaustive overview of emerging technologies & relevant startups within a specific field in just a few clicks.
The Story of MiBiome
The Story of MiBiome reflects the life story of our founder and CEO, Ms Milana Anash.
Milana Anash from northern Israel, is a biotechnology engineer with a master’s degree in business administration, and worked for many years in the pharmaceutical industry in both research and managerial positions.
The turning point in her life was reached, quite surprisingly, at a party with friends in 2016. As Milana tells it, “They knew I worked in the pharmaceutical industry, and a friend at the party approached me and begged, ‘Can’t you develop something to help my psoriasis? You know, I’ve been suffering for years, not going to the pool with my wife and kids, not enjoying life, being the object of endless looks and questions ‘Is it contagious?’ and suffering from the unbearable itch and pain which prevents me from sleeping at night. I’ve tried everything!’”
Her friend’s plea kept her up at night. “I was looking for a solution, a new outside the-box approach, a groundbreaking insight which led me to the study of the dermal microbiome , or skin probiotics for short.
“More precisely, my research found that the bacterial population on the skin of psoriasis sufferers, differs from the population found on healthy skin. Specifically, one important family of bacteria is missing. I found a safe bacterium from that family, already in commercial use in the food industry that can help restore the skin’s healthy dermal microbiome and we developed it into a topical, oil based suspension formulation. After proving the safety of the new formulation, we were able to register the product as a cosmetic.
“There are trillions of bacteria in the world and it could take centuries to find the right one, which is effective and safe – a unique combination. Throughout my extensive research I felt that I was being guided through divine intervention. Out of hundreds of articles – I read the right ones. Out of thousands of possible formulations – I found the right one. I am so thankful to G-d that brought me this opportunity to help people.”
In January 2018, Ms. Anash founded ClearSkin Ltd., the company that developed and commercially manufactures MiBiomeTM, containing those good bacteria (skin probiotics) and improves the skin quality and well-being of people suffering from conditions like psoriasis, atopic dermatitis, red and irritated skin, pruritis and more. The company registered a patent on this novel invention, and received funding from the Israeli Innovation Authority in recognition of the novelty, creativity and innovation that this advance represents.
The success of MiBiomeTM has brought it to prominence in the scientific and medical arenas. Milana has attended and spoken before conferences in Israel, Europe and the USA, where she has lectured on the relevance of the skin microbiome and probiotics in the field of dermatological cosmetics.
Ms. Anash and the product she developed have been widely acclaimed by patients and physicians alike. MiBiomeTM has been commercially available in pharmacies and natural products outlets in Israel since mid-2018, reaching more patients every month. MiBiomeTM was launched internationally in 2019 and is making excellent progress in global markets.
Is beating the “bad” bacteria will be the medical treatment of tomorrow?
Skin conditions? We’re all familiar with the conventional treatments available today. Creams and ointments, with and without steroids, phototherapy treatments, biological injections, immunosuppressive pills and treatments at the Dead Sea. Many scientists around the world have been working for decades to find a breakthrough and discover an effective and safe solution to psoriasis. So, after trying everything, are there new directions for research? And what will be the treatment of the future?
What is a microbiome?
The “microbiome” is an emerging field of research, primarily studied in recent years in the context of the digestive system, but is in its infancy with respect to the microbiome of the skin. What is a microbiome? It is a collection of trillions of microorganisms, such as bacteria, fungi and even viruses that live inside our bodies and on our skin. The total weight of the microbiome is between 2 and 3 kg per person! According to this novel approach, we are actually beginning to view and treat the microbiome as an integral organ of the human body.
But what is the impact of the microbiome on our lives? Can bacteria actually be the cause of skin conditions? Does the composition of the bacterial population found on the surface of the skin vary significantly from person to person or between areas of the body? These questions and others are being investigated by scientists around the world who are busy studying the microbiome. Indeed, recent studies do point to differences in the population of bacteria between healthy skin and unhealthy skin.
Does “bad” bacteria cause the problem?
Researchers have succeeded in identifying the “bad” bacterial populations that are common in cases of various skin disorders. Are the “bad” bacteria the root of the problem? Researchers continue their laboratory experiments and mapping work to solve these mysteries, characterize the mechanisms of action and work on developing appropriate innovative treatments. An Israeli venture set up to treat chronic skin diseases was a leader in the field to patent a breakthrough invention. The project, with the support of the Israeli Innovation Authority, has developed a bacterial complex, a kind of probiotic for the skin, which balances the dermal microbiome, in other words, replaces the “bad” bacteria on the skin with “good” bacteria. In a clinical trial, impressive success was recorded – 80% of the cases treated showed a positive effect on the PASI index after using the treatment twice a day for 8 weeks! The company is continuing its research to adapt the treatment to different skin types and further increase the success rate of treatment. The challenge is great and we believe in and hope for further breakthroughs in the treatment of chronic skin diseases!
Original article in Hebrew was published in Israeli Psoriasis Association magazine.